Cargando…

Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson’s Disease Model

The α-synuclein aggregates are the main component of Lewy bodies in Parkinson’s disease (PD) brain, and they showed immunotherapy could be employed to alleviate α-synuclein aggregate pathology in PD. Recently we have generated DNA aptamers that specifically recognize α-synuclein. In this study, we f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Xiaoxi, Zhao, Yun, Xue, Fenqin, Zheng, Yan, Huang, Haixia, Wang, Wei, Chang, Yongchang, Yang, Hui, Zhang, Jianliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709346/ https://www.ncbi.nlm.nih.gov/pubmed/31437653 http://dx.doi.org/10.1016/j.omtn.2019.07.008

Ejemplares similares

Novel DNA Aptamers for Parkinson’s Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation
por: Zheng, Yuan, et al.
Publicado: (2018)

Acceleration of α-Synuclein Aggregation by Exosomes
por: Grey, Marie, et al.
Publicado: (2015)

Modulation of α-Synuclein Aggregation In Vitro by a DNA Aptamer
por: Tran, Claire H., et al.
Publicado: (2022)

Models of α-synuclein aggregation in Parkinson’s disease
por: Giráldez-Pérez, Rosa María, et al.
Publicado: (2014)

Clinical Neuropathology image 5-2014: α-synuclein pathology in the ependyma in Parkinson’s disease
por: Kovacs, Gabor
Publicado: (2014)

Neuropathology in Mice Expressing Mouse Alpha-Synuclein
por: Rieker, Claus, et al.
Publicado: (2011)

Exosome release and neuropathology induced by α-synuclein: new insights into protective mechanisms of Drp1 inhibition
por: Fan, Rebecca Z., et al.
Publicado: (2019)

Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies
por: Stuendl, Anne, et al.
Publicado: (2016)

Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers
por: Boi, Laura, et al.
Publicado: (2020)

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
por: Tatenhorst, Lars, et al.
Publicado: (2016)

MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson’s disease
por: Geng, Lu, et al.
Publicado: (2023)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
por: Emin, Derya, et al.
Publicado: (2022)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

The Aggregation of Huntingtin and α-Synuclein
por: Chánez-Cárdenas, María Elena, et al.
Publicado: (2012)

Monitoring α-synuclein aggregation
por: Estaun-Panzano, Juan, et al.
Publicado: (2023)

PINK1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit and α-Synuclein Aggregation in Cell Culture Models of Parkinson's Disease
por: Liu, Wencheng, et al.
Publicado: (2009)

Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson’s disease model
por: Alwani, Anna, et al.
Publicado: (2023)

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
por: Javed, Hayate, et al.
Publicado: (2019)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Dynamics of a model for the degradation mechanism of aggregated α-synuclein in Parkinson's disease
por: Yang, Bojie, et al.
Publicado: (2023)

Anionic Nanoplastic Contaminants Promote Parkinson’s Disease-Associated α-Synuclein Aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Walking deficits and centrophobism in an α-synuclein fly model of Parkinson's disease1
por: Chen, A Y, et al.
Publicado: (2014)

Spreading of Aggregated α-Synuclein in Sagittal Organotypic Mouse Brain Slices
por: Uçar, Buket, et al.
Publicado: (2022)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
por: Lv, Yi-Qing, et al.
Publicado: (2022)

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
por: Schulz-Schaeffer, Walter J.
Publicado: (2010)

Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients
por: Luo, He-Ting, et al.
Publicado: (2016)

Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease
por: Rademacher, David J.
Publicado: (2023)

New Roles of Glycosaminoglycans in α-Synuclein Aggregation in a Cellular Model of Parkinson Disease
por: Lehri-Boufala, Sonia, et al.
Publicado: (2015)

Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease
por: Basu, Sambuddha, et al.
Publicado: (2015)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
por: Recasens, Ariadna, et al.
Publicado: (2018)

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
por: Wang, Zerui, et al.
Publicado: (2020)

Inflammatory Responses to Monomeric and Aggregated α-Synuclein in Peripheral Blood of Parkinson Disease Patients
por: Piancone, Federica, et al.
Publicado: (2021)

Mechanisms of enhanced aggregation and fibril formation of Parkinson’s disease-related variants of α-synuclein
por: Ohgita, Takashi, et al.
Publicado: (2022)

Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson’s disease
por: Hideshima, Makoto, et al.
Publicado: (2022)

Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease
por: Bongianni, Matilde, et al.
Publicado: (2022)

Kinetics of α-synuclein prions preceding neuropathological inclusions in multiple system atrophy
por: Woerman, Amanda L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c2rble95u5prm9nf0dd62pmf5t